How a stress-related brain circuit may drive opioid relapse in chronic pain
Amygdala kappa opioid system involvement in opioid relapse in pain states
This research looks at how a stress-related system in the amygdala may cause people with chronic pain to relapse on opioids.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11294304 on NIH RePORTER |
What this research studies
From the patient's view, researchers are studying cells and circuits in the amygdala that use kappa-opioid signals and stress chemicals (like dynorphin and CRF) to see how pain and past opioid use create intense negative feelings that trigger relapse. They use laboratory and animal models to map a pain-to-amygdala pathway and to turn kappa-opioid signals up or down to see how that changes drug-seeking behavior after withdrawal. The team links these brain changes to behaviors that resemble relapse and tests whether blocking kappa-opioid signaling reduces relapse-like actions. Results are aimed at guiding new ways to lower relapse risk for people with chronic pain who have used opioids.
Who could benefit from this research
Good fit: People with ongoing chronic pain who are using or have a history of using prescription opioids and who are concerned about relapse would be the most relevant group.
Not a fit: People without chronic pain or without current or past opioid exposure, or whose relapse risk is driven primarily by social or environmental factors, are less likely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this work could point to treatments that reduce relapse risk in people with chronic pain by targeting kappa-opioid or stress-related signaling in the brain.
How similar studies have performed: Preclinical studies have previously linked kappa-opioid and stress-system activity to negative mood and relapse-like behavior, but clinical treatments targeting kappa receptors remain largely unproven in people.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Cahill, Catherine M — University of California Los Angeles
- Study coordinator: Cahill, Catherine M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.